Breast Cancer and Life Insurance Underwriting

Can Someone With a History of Breast Cancer Qualify for Standard Life Insurance Rates?

Yes. Selected early-stage breast cancer histories can be highly insurable, and some may qualify for Standard consideration after appropriate treatment and follow-up. The strongest underwriting cases usually combine favorable tumor grade, localized stage, complete treatment, negative lymph nodes, reassuring receptor biology and sufficient time since the last active treatment without recurrence.

The Three Underwriting Anchors. For breast cancer, three issues deserve extraordinary attention: 1) Tumor grade — how aggressive the cancer looks under the microscope; 2) Treatment — what was required to control it and whether treatment was complete; and 3) Time since last treatment — because the underwriting risk generally improves as a recurrence-free interval accumulates. Stage, lymph nodes, receptor status and recurrence history then refine that core assessment.

Why Breast Cancer Underwriting Requires More Than the Stage Number

Breast cancer is the most common cancer in U.S. women other than skin cancer. For 2026, approximately 321,910 new invasive breast cancers and 60,730 cases of ductal carcinoma in situ (DCIS) are expected in women. Breast cancer also occurs in men, although it represents fewer than 1% of U.S. breast cancers.

The phrase "history of breast cancer" covers a very wide spectrum. A completely excised low-grade DCIS lesion is not the same underwriting risk as a Grade 3 invasive tumor with positive lymph nodes, and neither resembles metastatic disease. Modern breast-cancer staging itself incorporates tumor size, lymph-node status, tumor grade and biomarkers such as ER, PR and HER2.

Advisor takeaway. Before shopping the case, get the pathology report. The underwriting story starts with the exact diagnosis, tumor grade, stage, lymph nodes, receptor status, treatment and the date active treatment ended.

The Eight Questions That Usually Drive the Decision

• Was the diagnosis in situ (such as DCIS) or invasive breast cancer?
• What was the tumor grade, and what Nottingham/Bloom-Richardson score was reported?
• What was the tumor size and final clinical/pathologic stage?
• Were sentinel or axillary lymph nodes negative, microscopically positive or clearly positive?
• What were the ER, PR and HER2 results, and was the tumor triple-negative?
• What treatment was required: lumpectomy, mastectomy, radiation, chemotherapy, endocrine therapy, targeted therapy or immunotherapy?
• What date did surgery, radiation and chemotherapy/other active treatment finish, and how long has the applicant remained recurrence-free?
• Has there been any local, regional or distant recurrence, positive margin, residual disease, or treatment-related complication?

Tumor Grade: One of the Most Important Rate Drivers

Tumor grade answers a different question from stage. Stage asks how far the cancer has spread. Grade asks how abnormal and aggressive the tumor looks under the microscope. In invasive breast cancer, the preferred grading method is the Nottingham system, also known as the modified Bloom-Richardson or Scarff-Bloom-Richardson system.

The pathologist scores three microscopic features: tubule formation, nuclear pleomorphism and mitotic count. Each receives a score from 1 (more favorable) to 3 (less favorable). The three scores are added. A total of 3–5 is Grade 1, 6–7 is Grade 2, and 8–9 is Grade 3.

• Grade 1 (Nottingham score 3–5), low grade / better differentiated — Most favorable grade. If stage is localized, nodes are negative and treatment is complete, this can materially improve the chance of Standard or a modest temporary extra.
• Grade 2 (score 6–7), intermediate grade — Middle category. Stage, nodes, receptor biology, treatment intensity and time since treatment become especially important.
• Grade 3 (score 8–9), high grade / poorly differentiated — More aggressive biology. Usually requires greater caution, often more elapsed time and potentially higher temporary or permanent ratings.

Why grade matters. Two applicants can both have Stage I breast cancer but have very different underwriting profiles. A small Grade 1, node-negative, hormone-receptor-positive tumor may be much more favorable than a similarly sized Grade 3 or triple-negative tumor. Grade should never be omitted from an informal inquiry.

DCIS has a different grading convention. For in situ breast tumors, registry/pathology reporting commonly uses low, intermediate and high nuclear grade rather than the invasive Nottingham Grade 1–3 system. High-grade DCIS can be more concerning than low-grade DCIS because it reflects more abnormal cellular features and may influence treatment and recurrence assessment.

Treatment and the Date of Last Treatment: The Underwriting Clock

Treatment is more than a checklist item. It provides indirect information about the original severity of the cancer and determines when the underwriting clock begins. Public field guidance specifically defines recovery in terms of years since completion of treatment and notes that waiting periods can vary by tumor type, stage and grade.

The underwriting clock. The date of diagnosis matters, but the date active treatment ended is often more important. A person diagnosed four years ago who finished chemotherapy six months ago may still be a very recent cancer risk from an underwriting standpoint.

• Lumpectomy / breast-conserving surgery — Often used for localized disease; final pathology and margins are critical. Follow-up: was the tumor completely excised, were margins clear, was radiation recommended/completed?
• Mastectomy — May be used for DCIS, larger/multifocal tumors or patient preference. Follow-up: final surgical pathology, lymph nodes and margin status.
• Radiation therapy — Common after breast-conserving surgery; may also be used for higher-risk disease. Follow-up: completion date, and left-sided chest radiation can prompt attention to long-term cardiac effects.
• Chemotherapy — Often signals higher recurrence risk, adverse biology, larger tumors, node involvement or use in a neoadjuvant strategy. Follow-up: exact drugs, completion date, response and late toxicities.
• Endocrine therapy — Tamoxifen or aromatase inhibitors are commonly used for hormone-receptor-positive disease, often for years. Follow-up: ongoing preventive/adjuvant therapy does not always mean active cancer; carrier treatment of the underwriting clock varies.
• HER2-targeted therapy — Used for HER2-positive disease and can substantially improve outcomes. Follow-up: completion date, cardiac monitoring and disease status.
• Immunotherapy / other systemic therapy — May be used in selected higher-risk or triple-negative disease. Follow-up: why it was required and whether therapy is complete.

A practical underwriting submission should separately list the dates of diagnosis, surgery, last radiation, last chemotherapy or other systemic anti-cancer treatment, and current endocrine or maintenance therapy. Do not simply write "treatment completed" without dates.

Illustrative Underwriting Timing After Breast Cancer

The following is directional, not a universal carrier grid. Public field guides show that breast-cancer waiting periods and extras can vary substantially, and the same stage can be treated differently depending on grade, nodal status, receptor biology, treatment and elapsed time.

• Favorable DCIS / carcinoma in situ, completely excised — A shorter interval after completion of treatment may be sufficient in selected cases. Potential Standard to temporary flat extra depending on grade, treatment and follow-up.
• Localized invasive, Grade 1, node-negative, favorable biology — Often strongest after active treatment is complete and an initial recurrence-free interval is documented. Can be among the best invasive cases; Standard or Standard plus temporary flat extra may be possible.
• Localized invasive, Grade 2, node-negative — Time since treatment carries more weight as tumor size, biomarkers and treatment intensity increase. Often case-specific: temporary flat extra and/or table rating may apply before the case matures.
• Grade 3 and/or triple-negative but localized — Higher early recurrence concern; underwriters generally want more elapsed time and stronger follow-up. Greater likelihood of postponement initially, followed by substandard or temporary-extra consideration if recurrence-free.
• Microscopic or limited node-positive disease — Nodal disease raises recurrence risk and usually lengthens the underwriting timeline. Often longer postponement and/or combined table plus temporary flat extra.
• Multiple positive nodes / locally advanced Stage II–III — Substantially greater recurrence concern. Longer postponement is common; later consideration may remain substandard and highly case-specific.
• Recurrent breast cancer — A new underwriting clock generally begins after treatment of recurrence and depends heavily on recurrence site and disease-free interval. Usually postpone during active evaluation/treatment.
• Metastatic / Stage IV disease — Active systemic disease rather than a remote history. Generally not considered for traditional fully underwritten coverage in published field guidance.

The rate improves with time — but not by time alone. A longer disease-free interval is favorable because recurrence risk is being observed over time. But elapsed time cannot erase adverse pathology. A five-year history of Grade 3, node-positive disease is not automatically equivalent to a five-year history of small Grade 1, node-negative disease.

ER, PR and HER2: Why Receptor Biology Changes the Underwriting Story

Breast cancer is routinely tested for estrogen receptors (ER), progesterone receptors (PR) and HER2. These biomarkers help physicians choose treatment and estimate prognosis. Current national medical guidance identifies stage, grade, ER/PR status and HER2 status as important clinical and pathologic prognostic features.

• Hormone receptor positive / HER2 negative — Often treated with endocrine therapy; many lower-grade luminal tumors fall here. Can be favorable, especially with low grade, negative nodes and reassuring recurrence-risk testing.
• HER2 positive — Historically more aggressive, but modern HER2-targeted therapy has improved outcomes substantially. Do not treat HER2 positivity alone as an automatic adverse verdict; review stage, grade, treatment response and time since treatment.
• Triple-negative — ER-, PR- and HER2-negative; tends to grow more quickly and recur more often than many other breast-cancer subtypes. Usually greater early underwriting caution and a stronger need for recurrence-free time.
• Unknown / incomplete biomarkers — Missing information limits risk stratification. Obtain the pathology report rather than guessing from treatment alone.

Population survival data also show meaningful differences by receptor subtype, but stage remains extremely powerful. For 2016–2022 data, localized female breast cancer had 100% five-year relative survival overall, while distant disease had 33.8%; subtype modifies these results further.

Lymph Nodes, Stage and Recurrence Scores

Lymph-node status. Sentinel-node or axillary-node findings are among the most important pathology details. Negative nodes support localized disease. Micrometastatic nodal involvement carries more risk than node-negative disease but is different from multiple macroscopic positive nodes. The underwriter should know the exact number of nodes examined and the exact number and size of positive deposits.

Stage. Breast-cancer stage is not based on tumor size alone. Modern prognostic staging combines TNM information with tumor grade and biomarkers. In practical underwriting, the stage provides the overall map, while grade, nodes and biomarkers explain the biology inside that stage.

Oncotype DX and other genomic recurrence scores. For selected early-stage hormone-receptor-positive, HER2-negative breast cancers, genomic assays such as Oncotype DX can estimate recurrence risk and help determine whether chemotherapy is likely to add benefit. The 21-gene Oncotype DX assay produces a Recurrence Score and has extensive clinical validation. A favorable recurrence score can add useful evidence when interpreted with the pathology and treatment record; it should not replace stage, grade, nodes or receptor status, but it may help distinguish two otherwise similar early-stage cases.

Case shopping tip. If an Oncotype DX, MammaPrint or similar genomic recurrence test was performed, include the result. It may explain why chemotherapy was omitted or recommended and gives the underwriter additional information about tumor biology.

Reusable Cancer Primer: How Tumor Coding Fits With Breast Cancer

Cancer registries use ICD-O morphology codes to identify the tumor type and whether it is in situ or malignant. A common breast example is 8500/2 for ductal carcinoma in situ and 8500/3 for invasive carcinoma of no special type, historically called infiltrating ductal carcinoma.

Easy way to read the code. 8500 tells us the basic ductal/NST histology. /2 means in situ. /3 means invasive malignant behavior. The code tells us WHAT the tumor is; it does not tell us the entire insurance risk.

For invasive breast cancer, the Nottingham grade then helps answer how aggressive the cells look. Stage explains how far the cancer has gone. ER/PR/HER2 and genomic testing help explain tumor biology and recurrence risk. Treatment and time since treatment show what was required to control the disease and how long that control has persisted.

• What is it? 8500/2 DCIS vs. 8500/3 invasive carcinoma — separates in situ from invasive disease and identifies histology.
• How aggressive does it look? Nottingham Grade 1, 2 or 3 — higher grade generally means more aggressive tumor biology.
• How far has it gone? TNM / prognostic Stage 0–IV and node status — stage and nodes are major predictors of recurrence and mortality.
• What biology drives it? ER, PR, HER2; triple-negative; genomic recurrence score — helps explain prognosis and why specific therapies were used.
• How was it treated? Surgery, radiation, chemotherapy, endocrine or targeted therapy — treatment intensity and completeness are central underwriting facts.
• How long has it stayed controlled? Time since last active treatment with no recurrence — the disease-free interval is a major timing and rating factor.

The reusable underwriting shortcut. Tumor code tells us WHAT it is. Grade tells us HOW aggressive it looks. Stage tells us HOW FAR it has gone. Biomarkers tell us HOW it behaves. Treatment tells us WHAT IT TOOK to control it. Time since treatment tells us HOW LONG that control has lasted.

From the Underwriting Sweet Spot to the Harder Cases

• Most favorable — Low/intermediate-grade DCIS, completely removed, clear follow-up, no invasive disease. May reach Standard consideration after appropriate recovery interval; some published examples use temporary flat extras early.
• Favorable invasive — Small Grade 1, node-negative, localized, favorable receptors, complete treatment, good follow-up. Best chance among invasive cancers for Standard or a modest temporary extra after adequate time.
• Intermediate — Grade 2 and/or larger localized tumor, node-negative, treatment complete. Often temporary flat extra or table rating until more recurrence-free time accumulates.
• Higher concern — Grade 3, triple-negative, HER2-positive requiring systemic therapy, lymphovascular invasion or close/positive margins. More likely postponement initially and more conservative rating later, depending on response and elapsed time.
• Node-positive — Microscopic to multiple positive regional nodes. Increasing nodal burden generally increases postponement and rating.
• Locally advanced / Stage III — Large/local extension and/or substantial nodal disease. Longer postponement and highly individualized substandard consideration.
• Recurrent / metastatic — Local/regional recurrence or distant spread. Active/recent recurrence usually postpones; metastatic disease is generally outside traditional fully underwritten consideration.

What an Advisor Should Collect Before Shopping a Breast Cancer Case

• Exact diagnosis and histology, including DCIS versus invasive disease.
• Date of diagnosis and age at diagnosis.
• Original biopsy and final surgical pathology reports.
• Tumor size and final clinical/pathologic stage.
• Nottingham/Bloom-Richardson grade and score if reported.
• ER, PR and HER2 results; note whether triple-negative.
• Lymph-node procedure, number examined, number positive and size of any nodal metastasis.
• Margin status and any lymphovascular invasion.
• All treatment: lumpectomy/mastectomy, radiation, chemotherapy, targeted therapy, immunotherapy and endocrine therapy.
• Exact dates treatment started and ended — especially the date of last surgery, radiation and systemic anti-cancer therapy.
• Any Oncotype DX, MammaPrint or other recurrence-risk/genomic result.
• Any local, regional or distant recurrence and any additional treatment.
• Most recent oncology follow-up, mammogram/breast imaging and current disease status.
• Any treatment-related cardiac, neurologic or other complications.

Do not submit only "breast cancer — treated." For underwriting purposes, that description is almost useless. A one-page pathology summary with grade, stage, nodes, receptors, treatment and exact treatment-completion date can completely change the quality of an informal inquiry.

Important Distinctions That Prevent Underwriting Mistakes

Grade is not stage. Grade describes microscopic aggressiveness. Stage describes extent of disease. A small cancer can still be high grade, and a lower-grade cancer can still be higher stage if it has spread to regional nodes.

Ongoing endocrine therapy does not necessarily mean ongoing active cancer. Hormone-receptor-positive breast cancer may be treated with tamoxifen or an aromatase inhibitor for years after surgery, radiation and/or chemotherapy. This may be adjuvant risk-reduction therapy rather than evidence of persistent malignancy. Underwriting definitions of "last treatment" vary, so the submission should distinguish completed active treatment from ongoing endocrine prevention.

Chemotherapy is both treatment and a severity clue. Chemotherapy can be curative/adjuvant and does not mean the applicant had metastatic disease. But its use often tells the underwriter that the original case had enough recurrence risk to justify systemic treatment. The indication matters as much as the drug list.

A negative lymph node result is not the same as "no nodes mentioned." Whenever possible, provide the sentinel-node or axillary-node pathology. Missing nodal information creates uncertainty that can worsen an informal indication.

Sources

1. iA Financial Group (Industrial Alliance), Field Underwriting Guide for Representatives — Breast Cancer / Cancer
2. Equitable, Field Underwriting Guide — Breast Cancer
3. NAILBA, Field Underwriting Guide Version 4.0 — Breast Cancer
4. National Cancer Institute, Breast Cancer Treatment (PDQ)
5. National Cancer Institute, Stages of Breast Cancer
6. American Cancer Society, Key Statistics for Breast Cancer, 2026
7. American Cancer Society, Key Statistics for Breast Cancer in Men, 2026
8. National Cancer Institute / SEER Training, Breast Grade
9. National Cancer Institute / SEER, Female Breast Cancer and Breast Cancer Subtypes
10. National Cancer Institute, Recurrent Breast Cancer
11. National Cancer Institute, Breast Cancer Diagnosis / Oncotype DX Breast Cancer Assay
12. National Cancer Institute / SEER, Types of Breast Histologies and ICD-O references

This material is provided for educational and informational purposes only and is not a guarantee of underwriting outcome, premium rate, insurability or availability of coverage. Life insurance underwriting guidelines vary substantially by carrier and may change over time. Individual decisions depend on the applicant's complete medical history, pathology, stage, tumor grade, receptor status, lymph-node findings, treatment, treatment-completion date, recurrence history, age, amount of insurance, product, state, other risk factors and carrier-specific underwriting guidelines. References to possible Standard, Preferred, rated, flat-extra, postponed or declined outcomes are illustrative only. Formal coverage and rate classifications can be determined only by the issuing insurance company after review of a complete application and required underwriting evidence.